Physician profile
Michael S Lesser
NPI 1760593032
$15,865.82
in general payments reported to CMS, 2019-2025
71 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,605 · 2020: $2,065 · 2021: $2,810 · 2022: $1,991 · 2023: $2,217 · 2024: $2,307 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,318 · Education: $76.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,317.81 |
| Education | $76.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,627.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,430.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,383.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,371.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $738.29 | 2019-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.11 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $692.22 | 2019-2025 | |
| Amgen INC. | $690.99 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $633.50 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $534.31 | 2019-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $459.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $426.00 | 2019-2023 | |
| Amarin Pharma, INC. | $417.03 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $409.36 | 2019-2023 | |
| Allergan, INC. | $355.80 | 2019-2020 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lesser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.